TY  - CONF

T1  - AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers

JO  - CANCER RESEARCH

PY  - 2018/01/01

AU  - Robertson JFR

AU  - Coleman RE

AU  - Cheung KL

AU  - Evans A

AU  - Holcombe C

AU  - Skene A

AU  - Rea D

AU  - Ahmed S

AU  - Jahan A

AU  - Kelly S

AU  - Horgan K et al

ED  - 

VL  - 78

IS  - 4

Y2  - 2025/10/10

ER  -